tadalafil has been researched along with bay 63-2521 in 2 studies
| Studies (tadalafil) | Trials (tadalafil) | Recent Studies (post-2010) (tadalafil) | Studies (bay 63-2521) | Trials (bay 63-2521) | Recent Studies (post-2010) (bay 63-2521) |
|---|---|---|---|---|---|
| 1,742 | 392 | 1,089 | 254 | 47 | 238 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Thenappan, T; Weir, EK | 1 |
| Chang, M; Gall, H; Grünig, E; Halank, M; Mielniczuk, L; Orozco-Levi, M; Tanabe, N; Vachiéry, JL; Vogtländer, K | 1 |
2 other study(ies) available for tadalafil and bay 63-2521
| Article | Year |
|---|---|
The Nitric Oxide Pathway-A Potential Target for Precision Medicine in Pulmonary Arterial Hypertension.
Topics: Cyclic GMP; Drug Therapy, Combination; Endothelins; Enzyme Activators; Humans; Hypertension, Pulmonary; Molecular Targeted Therapy; Nitric Oxide; Phosphodiesterase 5 Inhibitors; Precision Medicine; Pyrazoles; Pyrimidines; Signal Transduction; Sildenafil Citrate; Tadalafil | 2017 |
Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH.
Topics: Aged; Aged, 80 and over; Chronic Disease; Drug Substitution; Enzyme Activators; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Pulmonary Embolism; Pyrazoles; Pyrimidines; Retrospective Studies; Sildenafil Citrate; Tadalafil | 2018 |